HIV coinfection with hepatitis c: Difference between revisions

	HIV coinfection with hepatitis c Microchapters
Home
Patient Information
Overview
Pathophysiology
Causes
Differentiating HIV coinfection with hepatitis c from other Diseases
Epidemiology and Demographics
Risk Factors
Natural History, Complications and Prognosis
Diagnosis
History and Symptoms
Physical Examination
Laboratory Findings
Treatment
Medical Therapy
Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
HIV coinfection with hepatitis c On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of HIV coinfection with hepatitis c All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on HIV coinfection with hepatitis c
CDC on HIV coinfection with hepatitis c
HIV coinfection with hepatitis c in the news
Blogs on HIV coinfection with hepatitis c
Directions to Hospitals Treating HIV coinfection with hepatitis c
Risk calculators and risk factors for HIV coinfection with hepatitis c

VisualWikitext

Latest revision as of 18:01, 18 September 2017

For main chapter on AIDS, click here

For main chapter on HIV, click here

For main chapter on Hepatitis C, click here

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-In-Chief: Varun Kumar, M.B.B.S. [2]

Overview

Pathophysiology

Causes

Differentiating HIV coinfection with hepatitis c from other Diseases

Epidemiology and Demographics

Risk Factors

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms | Physical Examination | Laboratory Findings

Treatment

Medical Therapy | Prevention | Cost-Effectiveness of Therapy | Future or Investigational Therapies

Case Studies

Case #1

Related Chapters

Template:WS Template:WH

@@ Line 1: / Line 1: @@
-{{Hepatitis C}}
+__NOTOC__
+{{HIV coinfection with hepatitis c}}
+'''For main chapter on AIDS, click [[AIDS|here]]'''
+'''For main chapter on HIV, click [[HIV|here]]'''
+'''For main chapter on Hepatitis C, click [[Hepatitis C|here]]'''
 {{CMG}}; {{AOEIC}} {{VK}}
-==Overview==
-In HIV–HCV co-infected patients, the Hepatitis C (HCV) viral load is higher than in HCV-mono-infected patients in both the plasma and liver tissue.
-==Cause of Co-infection==
+==[[HIV coinfection with hepatitis c overview|Overview]]==
-Patients who are HIV-positive are commonly co-infected with HCV due to the following:
-*Shared routes of transmission.
-*Percutaneous exposure to blood.
-*Sexual intercourse.
-*From a mother to her infant.
-==Natural History==
+==[[HIV coinfection with hepatitis c pathophysiology|Pathophysiology]]==
-The effect of HCV on the natural history of HIV remains inconclusive due to contradictory studies documenting no effect, while others show an increase to an AIDS defining illness or death. The morbidity and mortality caused by HCV has increased since the inception of highly active antiretroviral therapy (HAART) because HIV patients are living longer from potent antiretroviral therapies and prophylaxis of traditional opportunistic infections. Infection with HCV can be asymptomatic, self-limiting, or progress to [[cirrhosis]] or [[Hepatocellular carcinoma|cancer]].
-==Treatment==
+==[[HIV coinfection with hepatitis c causes|Causes]]==
-The '''primary objective''' of HCV therapy is permanent eradication of the virus. The '''secondary''' potential benefit of eradication is a reduction in the risk of liver failure and liver cancer.
-===Regimen===
+==[[HIV coinfection with hepatitis c differential diagnosis|Differentiating HIV coinfection with hepatitis c from other Diseases]]==
-==Recommendations for Diagnosis and Treatment of Persons with HIV Coinfection: AASLD Practice Guidelines 2009<ref name="pmid19554546">{{cite journal |author=Swan T, Curry J |title=Comment on the updated AASLD practice guidelines for the diagnosis, management, and treatment of hepatitis C: treating active drug users |journal=[[Hepatology (Baltimore, Md.)]] |volume=50 |issue=1 |pages=323–4; author reply 324–5 |year=2009 |month=July |pmid=19554546 |doi=10.1002/hep.23077 |url=http://dx.doi.org/10.1002/hep.23077 |accessdate=2012-02-21}}</ref>==
+==[[HIV coinfection with hepatitis c epidemiology and demographics|Epidemiology and Demographics]]==
-{{cquote|
-'''1.''' Anti-HCV testing should be performed in all HIV-infected persons ''(Class I, Level B)''.
-'''2.''' HCV RNA testing should be performed to conﬁrm HCV infection in HIV-infected persons who are positive for anti-HCV, as well as in those who are negative and have evidence of unexplained liver disease ''(Class I, Level B)''.
+==[[HIV coinfection with hepatitis c risk factors|Risk Factors]]==
-'''3.''' Hepatitis C should be treated in the HIV/HCV co-infected patient in whom the likelihood of serious liver disease and a treatment response are judged to outweigh the risk of morbidity from the adverse effects of therapy ''(Class I, Level A)''.
+==[[HIV coinfection with hepatitis c natural history, complications and prognosis|Natural History, Complications and Prognosis]]==
-'''4.''' Initial treatment of hepatitis C in most HIV infected patients should be peginterferon alfa plus ribavirin for 48 weeks at doses recommended for HCV mono-infected patients  ''(Class I, Level A)''.
+==Diagnosis==
-'''5.''' When possible, patients receiving [[zidovudine]] (AZT) and especially didanosine (ddI) should be switched to an equivalent antiretroviral agent before beginning therapy with ribavirin ''(Class I, Level C)''.
+[[HIV coinfection with hepatitis c history and symptoms|History and Symptoms]] | [[HIV coinfection with hepatitis c physical examination|Physical Examination]] | [[HIV coinfection with hepatitis c laboratory findings|Laboratory Findings]]
-'''6.''' HIV-infected patients with decompensated liver disease (CTP Class B or C) should not be treated with peginterferon alfa and ribavirin and may be candidates for liver transplantation ''(Class IIa, Level C)''.}}
+==Treatment==
-==References==
+[[HIV coinfection with hepatitis c medical therapy|Medical Therapy]] | [[HIV coinfection with hepatitis c prevention|Prevention]] | [[HIV coinfection with hepatitis c cost-effectiveness of therapy|Cost-Effectiveness of Therapy]] | [[HIV coinfection with hepatitis c future or investigational therapies|Future or Investigational Therapies]]
-{{reflist|2}}
-{{WS}}
+==Case Studies==
-{{WH}}
+[[HIV coinfection with hepatitis c case study one|Case #1]]
-[[Category:Hepatitis|C]]
+==Related Chapters==
-[[Category:Gastroenterology]]
-[[Category:Infectious disease]]
-[[Category:Disease]]
-==References==
+* [[Coinfection]]
-{{reflist|2}}
+* [[AIDS]]
+* [[HIV disease]]
+* [[Hepatitis B with HIV coinfection]]
+* [[Tuberculosis and HIV coinfection]]
+* [[HIV and tuberculosis coinfection : drug interaction]]
+* [[HIV and pregnancy]]
+* [[Hepatitis]]
 {{WS}}
@@ Line 52: / Line 50: @@
 [[Category:Hepatitis|C]]
 [[Category:Gastroenterology]]
-[[Category:Infectious disease]]
 [[Category:Disease]]